CellGENTherapies

Manufacturing Process

Currently, CellGENTherapies is expanding its capabilities by developing the technology and quality control assays for production of CAR T in-house and aims to obtain a production license from the regulatory agency for gene therapy. Furthermore, CellGENTherapies is setting up the required technology and infrastructure to manufacture in-house lentiviral particles.